Capricor Therapeutics, Inc. (NASDAQ:CAPR) belongs to Healthcare sector. Its weekly performance is -2.50%. On last trading day company shares ended up $4.68. Capricor Therapeutics, Inc. (NASDAQ:CAPR) distance from 50-day simple moving average (SMA50) is -22.39%. On 17 June, Capricor Therapeutics, Inc. (NASDAQ:CAPR) announced the appointment of Houman Hemmati, M.D., Ph.D. to the newly created position of Vice President of Medical and Clinical Development for New Therapies. In this role, Dr. Hemmati will work to drive promising new therapies such as Capricor’s exosome platform into clinical development as he works closely with the R&D, manufacturing and product development teams.
Liquid Biopsy Biomarker Identifies Patients with Improved Response to PARP Inhibition in Metastatic Castrate Resistant Prostate Cancer
19 days ago